BlackRock Inc. grew its holdings in shares of Sage Therapeutics, Inc. (NASDAQ:SAGE) by 5.9% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 3,031,548 shares of the biopharmaceutical company’s stock after purchasing an additional 168,424 shares during the quarter. BlackRock Inc. owned approximately 8.12% of Sage Therapeutics worth $241,431,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also made changes to their positions in SAGE. Russell Investments Group Ltd. boosted its stake in Sage Therapeutics by 82.1% during the 1st quarter. Russell Investments Group Ltd. now owns 19,679 shares of the biopharmaceutical company’s stock worth $1,399,000 after purchasing an additional 8,872 shares during the last quarter. Swiss National Bank boosted its stake in Sage Therapeutics by 3.2% during the 1st quarter. Swiss National Bank now owns 52,100 shares of the biopharmaceutical company’s stock worth $3,703,000 after purchasing an additional 1,600 shares during the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS acquired a new stake in Sage Therapeutics during the 1st quarter worth $355,000. Parametric Portfolio Associates LLC boosted its stake in Sage Therapeutics by 31.2% during the 1st quarter. Parametric Portfolio Associates LLC now owns 24,576 shares of the biopharmaceutical company’s stock worth $1,747,000 after purchasing an additional 5,842 shares during the last quarter. Finally, Ameritas Investment Partners Inc. acquired a new stake in Sage Therapeutics during the 1st quarter worth $180,000.

Sage Therapeutics, Inc. (NASDAQ:SAGE) opened at 63.69 on Friday. Sage Therapeutics, Inc. has a 52-week low of $38.30 and a 52-week high of $90.80. The firm has a 50-day moving average of $73.34 and a 200-day moving average of $74.38. The firm’s market cap is $2.38 billion.

Sage Therapeutics (NASDAQ:SAGE) last issued its quarterly earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($1.88) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.63) by ($0.25). During the same period in the previous year, the business earned ($1.08) earnings per share. Equities analysts anticipate that Sage Therapeutics, Inc. will post ($7.37) EPS for the current year.

Several equities research analysts have issued reports on the stock. Royal Bank Of Canada assumed coverage on shares of Sage Therapeutics in a research note on Thursday, September 14th. They set an “outperform” rating and a $117.00 target price on the stock. BMO Capital Markets lifted their target price on shares of Sage Therapeutics from $80.00 to $84.00 and gave the stock an “outperform” rating in a research note on Thursday, September 14th. Chardan Capital reaffirmed a “hold” rating on shares of Sage Therapeutics in a research note on Wednesday, September 13th. Needham & Company LLC lowered their target price on shares of Sage Therapeutics from $95.00 to $86.00 and set a “buy” rating on the stock in a research note on Wednesday, September 13th. Finally, Stifel Nicolaus reaffirmed a “buy” rating and set a $91.00 target price (down previously from $104.00) on shares of Sage Therapeutics in a research note on Wednesday, September 13th. Four investment analysts have rated the stock with a hold rating, ten have given a buy rating and two have assigned a strong buy rating to the stock. Sage Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $86.77.

COPYRIGHT VIOLATION WARNING: “BlackRock Inc. Acquires 168,424 Shares of Sage Therapeutics, Inc. (SAGE)” was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this news story on another publication, it was illegally copied and reposted in violation of international trademark & copyright laws. The original version of this news story can be read at https://www.thecerbatgem.com/2017/10/06/blackrock-inc-acquires-168424-shares-of-sage-therapeutics-inc-sage.html.

Sage Therapeutics Profile

SAGE Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. The Company’s lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the Gamma-Amino Butyric Acid-A (GABAA) receptor.

Want to see what other hedge funds are holding SAGE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sage Therapeutics, Inc. (NASDAQ:SAGE).

Institutional Ownership by Quarter for Sage Therapeutics (NASDAQ:SAGE)

Receive News & Stock Ratings for Sage Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sage Therapeutics Inc. and related stocks with our FREE daily email newsletter.